Navigation Links
Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
Date:12/19/2007

ZURICH, Switzerland, December 19 /PRNewswire/ -- An exclusive license for the development and commercialisation of a drug delivery system for lung infections in Cystic Fibrosis patients was signed today. As part of the agreement, aRigen Pharmaceuticals Inc., Japan transferred relevant rights to Axentis Pharma AG of Switzerland. The EMEA has already granted orphan drug status to the licensed technology and a phase II clinical trial will be initiated by Axentis Pharma AG in early 2008.

Axentis Pharma AG (Switzerland) and aRigen Pharmaceuticals, Inc. (Japan) announced today the signature of a license agreement for the development of therapy against lung infections in Cystic Fibrosis patients. Under the terms of the agreement Axentis Pharma AG purchased from aRigen Pharmaceuticals, Inc. an exclusive license for the development and commercialisation of ARB-CF0223 worldwide except Japan and Korea. ARB-CF0223 is a fully patented, innovative encapsulating drug delivery system for the treatment of pulmonary infections in patients with Cystic Fibrosis. The system has an improved safety profile, higher efficacy and lower doses, and also reduces the frequency and severity of exacerbations compared to current treatments for pulmonary infections in patients with Cystic Fibrosis. As part of the agreement aRigen Pharmaceuticals, Inc. received shares of Axentis Pharma plus an undisclosed sum in cash.

Jorg Zielasek, President of Axentis Pharma AG, commented that: "The purchase of the license from aRigen Pharmaceuticals grants Axentis the right to further develop and commercialise an extremely promising treatment for chronic lung inflammation, the most severe consequence of Cystic Fibrosis. The agreement means that Axentis can now initiate an immediate phase II clinical trial in Germany. The design of the study has already been approved by the EMEA, which has also granted orphan drug status to ARB-CF0223. This is a very promising prospect for both Cystic Fibrosis
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
3. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. Pharsight Achieves First License Sale for Public-Source Database
8. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
9. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
10. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...e-FirstCall/--Sigma-AldrichCorporation(Nasdaq: SIA...ay,December1stat1:45PMGMTinLondon,7:45AMUS/CST.Int...eInternetavailableat http://inve s tor.sig m ...oaccessthisfile. ,, AboutSigma-Aldrich: Sigm...pany.Itschemicalandbiochemicalproductsandkitsareus...
(Date:11/24/2009)...e-Asia/--ShanghaiBiolaxyannouncedthe,ChineseStateF...estigationalnewdrugapplication(IND)foritsoralinsul...otreatdiabetes.ThisIND,approvalallowsBiolaxytoinit...adisordercharacteristicofhighbloodglucoseandpoor,m...everemicro-and,macro-vasculardiseases,lossofvision...
(Date:11/24/2009)...ire-FirstCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),...nnouncedthatithassubmittedaMAAtotheEuropeanMedicin...placementtherapyindevelopment,forthetreatmentofTyp...onforvelaglucerasealfathathasbeensubmitted,withpre..., Basedonaglobalsupplyshortageofthecurrentlyapprov...
(Date:11/24/2009)...l Abstracts Service (CAS), the global expert on ch...fice is now the world,s leading producer of patent...d Japan,s patent office, the World Intellectual Pr...Patent and Trademark Office (USPTO) for more than ...06, and exceeded Japan for the first time on a mon...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3
...x,BioTherapeutics, Inc. (Amex: PLX ), today annou...nd Chief Executive Officer, will present at the CI.... Dr. Aviezer,s presentation,will take place at 3:...-Astoria Hotel in New York City. Dr. Aviezer,s pr...at, http://www.veracast.com/webcasts/cibcwm/health...
...onfirmed, REINACH and BASEL, Switzerland, Novembe...posters on its late-stage,investigational antibiot...l,Pharmacology (Verbund Klinische Pharmakologie - ...ermany. The posters presented at the conference,fu...aprim that is already,available. At two recent con...
... Inc. (OTC,Bulletin Board: SYMD), a biomaterials c...ation of anti-adhesion and drug delivery products,...nd CEO, will present at,the ACUMEN BioFin 9th Annu...05 PM, EDT, at the New York Palace Hotel in New Yo...w. The presentation will be available via web cas...
Other Biology Technology:Protalix BioTherapeutics to Present at CIBC World Markets 18th Annual Healthcare Conference 2Arpida Presents Data on Iclaprim at Scientific Congress in Germany 2Arpida Presents Data on Iclaprim at Scientific Congress in Germany 3Arpida Presents Data on Iclaprim at Scientific Congress in Germany 4
(Date:11/23/2009)...ATINew research presents strong evidence that the ...h outdoor traffic-related pollution and indoor end...ne or the other exposure alone. , Environmenta...i (UC) College of Medicine have shown that childre...articles and indoor endotoxin during early life ar...
(Date:11/23/2009)... study by the Wildlife Conservation Society says t...mp in the Republic of Congopart of the "mother lod...earare becoming increasingly threatened by growing...mmends protection of the swamp forests adjacent to...after recent surveys confirmed that high densities...
(Date:11/23/2009)... Iowa - The only swine vaccine available for the H...infected with the virus. The vaccination marks the...diagnosed with the pandemic flu., Iowa State Uni..., developed the vaccine this summer and has been s...a, Kansas and Illinois for several weeks., The l...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Mach 7 Technologies and QStar Sign Agreement to Deliver PACS Neutral Solutions Through Mutual Channel Partner Data Distributing 6414 1Mach 7 Technologies and QStar Sign Agreement to Deliver PACS Neutral Solutions Through Mutual Channel Partner Data Distributing 6414 2Mach 7 Technologies and QStar Sign Agreement to Deliver PACS Neutral Solutions Through Mutual Channel Partner Data Distributing 6414 3Mach 7 Technologies and QStar Sign Agreement to Deliver PACS Neutral Solutions Through Mutual Channel Partner Data Distributing 6414 4Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 6412 1Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 6412 2Impliant Announces the Addition of Vice President of Clinical and Regulatory Affairs to Executive Management Team 6412 3Sounds May Help Solidify Memories While Asleep 61735 1Sounds May Help Solidify Memories While Asleep 61735 2
...J. In a paper published in the journal Nature t... Bruggmann, and a team of international collaborat...t-tolerant African grass. The findings could one d...or arid regions with rapidly expanding human popul...ector of the Waksman Institute of Microbiology at ...
...ble in French . , Lack of sleep is a common co... during the day poses a very real and dangerous pr...Institute (MNI) at McGill University demonstrates ...d by two different types of nerve cells (neurons),...rexin (Orx) neurons, which occupy the same region ...
...o has ever battled a stuck zipper knows it,s a goo... and then to pull hard. , A Cornell research team,...A molecules. By mapping the hiccups, stoppages and...t into how genes are packed and expressed within c...ping of histone-DNA interactions in a nucleosome,"...
Other Biology News:Sequencing of sorghum genome completed 2What happens when we sleep 2Researchers 'unzip' molecules to measure interactions keeping DNA packed in cells 2
Microarray Spotting Solution for Silane Coated Slides from Sigma-Aldrich
...es fully automated hybridization of microarrays on... designed to offer researchers improved reproducib...essary to perform a wide range of applications. I...aturations of up to 99C. The possibility of 6 on-b...
...g Kit generates labeled cDNA for use in microarray...is made via a reverse transcription from mRNA into...ods, there are no unnatural modified nucleotides u...modified cDNA is then labeled in a one step 30 min...
...Blot Kits overcome this limitation and offer high ... range in low-density protein array (96- and 384-s...rming reverse-phase protein arrays and for profili...ndant antigens. Protein Detector kits are based on...
Biology Products: